Additionally, in a LL-37-induced rosacea mouse model, treatment with VP alleviated the clinical symptoms of rosacea, highlighting YAP as a potential therapeutic target for this inflammatory skin disease (100). Here, YAP1 is linked to inflammatory skin disease.